Cogent Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cogent Biosciences sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Cogent Biosciences: 12 sponsored US clinical trials, 4 recruiting.
Cogent Biosciences sponsors 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Gastrointestinal Stromal Tumors, with 1 trials.
Top-decile sponsor footprint
Cogent Biosciences ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
NCT03680560
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03266692
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
NCT03189836
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
NCT02840110
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT02776813
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
NCT02401815
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the Cogent Biosciences pipeline
4 recruiting of 12 indexed (33% open); 2 completed (17%).
Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Advanced Gastrointestinal Stromal Tumors (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cogent Biosciences: open-pipeline peers nationwide
Peers matched on 12 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Cogent Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Cogent Biosciences page
12 registered trials is a research-attention snapshot, not an endorsement of Cogent Biosciences or any single study.
- 4 of Cogent Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Gastrointestinal Stromal Tumors is the condition Cogent Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Gastrointestinal Stromal Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Cogent Biosciences pipeline card: 12 registered trials from official public datasets.Report a data error.